{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Fatigue"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The NCI Common Toxicity Criteria for Adverse Events (version 3.0) were used to define and grade toxicity for patients.","groups":[{"description":"Dose Level 1 (30 mg/m2 + 30 mg/m2), Dose Level 2 (30 mg/m2 + 50 mg/m2), Dose Level 3 (50 mg/m2 + 50 mg/m2)\n\nPHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.\n\nalvocidib: Given IV","id":"OG000","title":"Dose Levels 1, 2, 3"}],"paramType":"NUMBER","populationDescription":"Grade 3 and 4 toxicities.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment","title":"Qualitative and Quantitative Toxicities in Regard to Organ Specificity","type":"PRIMARY","unitOfMeasure":"percentage of patients"}